238 related articles for article (PubMed ID: 33862110)
1. Roles of microRNAs in renal disorders related to primary podocyte dysfunction.
Iranzad R; Motavalli R; Ghassabi A; Pourakbari R; Etemadi J; Yousefi M
Life Sci; 2021 Jul; 277():119463. PubMed ID: 33862110
[TBL] [Abstract][Full Text] [Related]
2. Renal microRNA- and RNA-profiles in progressive chronic kidney disease.
Rudnicki M; Perco P; D Haene B; Leierer J; Heinzel A; Mühlberger I; Schweibert N; Sunzenauer J; Regele H; Kronbichler A; Mestdagh P; Vandesompele J; Mayer B; Mayer G
Eur J Clin Invest; 2016 Mar; 46(3):213-26. PubMed ID: 26707063
[TBL] [Abstract][Full Text] [Related]
3. The role of B7-1 in proteinuria of glomerular origin.
Novelli R; Benigni A; Remuzzi G
Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
[TBL] [Abstract][Full Text] [Related]
4. [Expression of neonatal Fc receptor on human nephritis and rat nephritis models].
Feng ST; Gan HL; Sun JY; Jiang T; Liu BL; Zhao ZH; Guo MY; Zhang ZG
Zhonghua Bing Li Xue Za Zhi; 2012 Feb; 41(2):81-5. PubMed ID: 22455882
[TBL] [Abstract][Full Text] [Related]
5. miR-217 Is a Useful Diagnostic Biomarker and Regulates Human Podocyte Cells Apoptosis via Targeting TNFSF11 in Membranous Nephropathy.
Li J; Liu B; Xue H; Zhou QQ; Peng L
Biomed Res Int; 2017; 2017():2168767. PubMed ID: 29214160
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory smads and tgf-Beta signaling in glomerular cells.
Schiffer M; Schiffer LE; Gupta A; Shaw AS; Roberts IS; Mundel P; Böttinger EP
J Am Soc Nephrol; 2002 Nov; 13(11):2657-66. PubMed ID: 12397035
[TBL] [Abstract][Full Text] [Related]
7. Fra-2 is a novel candidate drug target expressed in the podocytes of lupus nephritis.
Xu C; Miao Y; Pi Q; Zhu S; Li F
Clin Immunol; 2018 Dec; 197():179-185. PubMed ID: 30296590
[TBL] [Abstract][Full Text] [Related]
8. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
[TBL] [Abstract][Full Text] [Related]
9. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
10. Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis.
Xiao B; Wang LN; Li W; Gong L; Yu T; Zuo QF; Zhao HW; Zou QM
Cell Death Dis; 2018 May; 9(5):533. PubMed ID: 29748623
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy.
Yang Y; Gubler MC; Beaufils H
Nephron; 2002 Jul; 91(3):416-23. PubMed ID: 12119471
[TBL] [Abstract][Full Text] [Related]
12. Patterns of renal involvement in a cohort of patients with inflammatory bowel disease in Egypt.
Elaziz MMA; Fayed A
Acta Gastroenterol Belg; 2018; 81(3):381-385. PubMed ID: 30350525
[TBL] [Abstract][Full Text] [Related]
13. microRNAs in chronic kidney disease.
Zhao H; Ma SX; Shang YQ; Zhang HQ; Su W
Clin Chim Acta; 2019 Apr; 491():59-65. PubMed ID: 30639583
[TBL] [Abstract][Full Text] [Related]
14. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases.
Ilatovskaya DV; Staruschenko A
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F393-7. PubMed ID: 26084930
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of fibroblast-specific protein-1 expression on podocytes in patients with focal segmental glomerulosclerosis.
Samejima K; Nakatani K; Suzuki D; Asai O; Sakan H; Yoshimoto S; Yamaguchi Y; Matsui M; Akai Y; Toyoda M; Iwano M; Saito Y
Nephron Clin Pract; 2012; 120(1):c1-7. PubMed ID: 22126861
[TBL] [Abstract][Full Text] [Related]
16. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.
Ramezani A; Devaney JM; Cohen S; Wing MR; Scott R; Knoblach S; Singhal R; Howard L; Kopp JB; Raj DS
Eur J Clin Invest; 2015 Apr; 45(4):394-404. PubMed ID: 25682967
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced glomerular diseases.
Garnier AS; Laubacher H; Briet M
Therapie; 2024; 79(2):271-281. PubMed ID: 37973491
[TBL] [Abstract][Full Text] [Related]
18. No complement receptor 1 stumps on podocytes in human glomerulopathies.
Moll S; Miot S; Sadallah S; Gudat F; Mihatsch MJ; Schifferli JA
Kidney Int; 2001 Jan; 59(1):160-8. PubMed ID: 11135068
[TBL] [Abstract][Full Text] [Related]
19. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.
Shi SF; Wang SX; Zhang YK; Zhao MH; Zou WZ
Ren Fail; 2008; 30(5):477-83. PubMed ID: 18569926
[TBL] [Abstract][Full Text] [Related]
20. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
